INZY insider transaction filings

Inozyme Pharma, Inc. — 16 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-07-03. Screen INZY transaction legs live →

FiledFormInsiderReported transactionsSource
2025-07-034Subramanian Sanjay — SVP, CFO & Head of BDCode (U): 39,701 @ $4 · Disposition to issuer (D): 38,500 (derivative) · Disposition to issuer (D): 180,000 (derivative) · Disposition to issuer (D): 135,000 (derivative) · Disposition to issuer (D): 145,000 (derivative)EDGAR
2025-07-034Winton Matthew — COOCode (U): 21,743 @ $4 · Disposition to issuer (D): 41,500 (derivative) · Disposition to issuer (D): 145,000 (derivative)EDGAR
2025-07-034Sullivan Lynne Marie — DirectorDisposition to issuer (D): 28,368 (derivative)EDGAR
2025-07-034Treco Douglas A — CEO & Chairman, DirectorCode (U): 43,861 @ $4 · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 86,979 (derivative) · Disposition to issuer (D): 400,000 (derivative)EDGAR
2025-07-034Bolte Axel — DirectorCode (U): 423,926 @ $4 · Disposition to issuer (D): 234,176 (derivative) · Disposition to issuer (D): 159,187 (derivative)EDGAR
2025-07-034Hopfner Robert Lorne — DirectorCode (U): 2,923,110 @ $4 · Code (U): 1,571,741 @ $4EDGAR
2025-06-274Winton Matthew — COOGrant/award (A): 14,355 @ $0.74EDGAR
2025-06-274Subramanian Sanjay — SVP, CFO & Head of BDGrant/award (A): 6,813 @ $0.74EDGAR
2025-06-274Treco Douglas A — CEO & Chairman, DirectorGrant/award (A): 2,815 @ $0.74EDGAR
2025-05-204Bolte Axel — DirectorOption exercise (M): 152,823 @ $0.98 · Option exercise (M): 4,407 @ $0.98 · Option exercise (M): 152,823 (derivative) @ $0 · Option exercise (M): 4,407 (derivative) @ $0EDGAR
2025-04-034Treco Douglas A — CEO & Chairman, DirectorOption exercise (M): 25,000 · Sale (S): 8,819 @ $0.89 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2025-04-024Winton Matthew — COOGrant/award (A): 2,490 @ $0.77EDGAR
2025-04-024Subramanian Sanjay — SVP, CFO & Head of BDGrant/award (A): 2,490 @ $0.77EDGAR
2025-03-174Subramanian Sanjay — SVP, CFOGrant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 38,500 (derivative) @ $0EDGAR
2025-03-174Winton Matthew — COOGrant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 41,500 (derivative) @ $0EDGAR
2025-03-174Treco Douglas A — CEO, DirectorGrant/award (A): 400,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR

Recent 8-K events — Inozyme Pharma, Inc.

FiledFormItems reportedSource
2025-07-018-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2025-06-238-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-06-028-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2025-05-168-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-05-148-K2.01 — Completion of Acquisition or Disposition of Assets
9.01 — Financial Statements and Exhibits
EDGAR
2025-03-108-K2.02 — Results of Operations and Financial Condition
?
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=INZY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →